Abstract

Background & Aims: Considerable debate exists concerning which isoform of nitric oxide synthase (NOS) is responsible for the increased production of NO in PHT. We used the portal vein ligation model of PHT in wild-type and eNOS- or iNOS-knockout mice to definitively determine the contribution of these isoforms in the development of PHT. Methods: The portal vein of wild-type mice, or those with targeted mutations in the nos2 gene (iNOS) or the nos3 gene (eNOS), was ligated and portal venous pressure (Ppv), abdominal aortic blood flow (Qao), and portosystemic shunt determined 2 weeks later. Results: In wild-type mice, as compared with sham-operated controls, portal vein ligation (PVL) resulted in a time-dependent increase in Ppv (7.72 ± 0.37 vs 17.57 ± 0.51 cmH 2O, at 14 days) concomitant with a significant increase in Qao (0.12 ± 0.003 vs 0.227 ± 0.005 mL/min/g) and portosystemic shunt (0.47% ± 0.01% vs 84.13% ± 0.09% shunt). Likewise, PVL in iNOS-deficient mice resulted in similar increases in Ppv, Qao, and shunt development. In contrast, after PVL in eNOS-deficient animals, there was no significant change in Ppv (7.52 ± 0.22 vs 8.07 ± 0.4 cmH 20) or Qao (0.111 ± 0.01 vs 0.14 ± .023 mL/min/g). However, eNOS (−/−) mice did develop a substantial portosystemic shunt (0.33% ± 0.005% vs 84.53% ± 0.19% shunt), comparable to that seen in wild-type animals after PVL. Conclusions: These data support a key role for eNOS, rather than iNOS, in the pathogenesis of PHT.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.